InNexus Biotechnology Inc., a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL), announced the addition of a new product designated DXLr120 (CD20). This is the third product added to the growing InNexus pipeline and was developed using new recombinant methods to produce a DXL anti CD20 antibody.
InNexus' first and second products were developed with chemical methods to impart DXL into the development of new antibodies and the latest product represents a significant patent expansion for the company.
InNexus chief scientific officer, Dr Thomas Kindt, said, "Within the past two years, InNexus has moved rapidly to accelerate preclinical development of multiple candidates. Use of recombinant methods to develop DXLr120 with our patented DXL technology demonstrates the expertise of our team and the opportunity we have to create multiple therapeutic and diagnostic antibodies."
DXLr120 significantly improves antibodies binding to CD20, the target for Non Hodgkin's Lymphoma and Rheumatoid Arthritis and joins InNexus' well-studied DXL625 (CD20). DXL625, developed with chemical methods, also significantly improves the binding of antibodies to CD20 and increases potency using both in vitro and in vivo studies. Preliminary data for DXLr120 already reveals properties akin to those shown for DXL625. Plans are underway to subject DXLr120 to the full battery of tests for potency, in vivo efficacy and safety used for DXL625.
Antibodies are protein molecules produced by our immune system. The shape of an antibody is often described in a Y shape and one of their critical roles is to recognize and attack foreign bacteria and viruses. Antibodies come in numerous forms and each type can recognize unique antigen (targets). Each arm of the antibody (upper portion of the Y) has unique molecular structure (keys) that combine with the targets. Attachment of many antibodies to an object with these targets ultimately causes its destruction. Recombinant technologies have seen an explosion in use as manufacturing procedures have streamlined with shortened time frames and the final product often has a greater quality than that of products from non-recombinant methods.
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.